A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct.

Peptides corresponding to the fusion site in 210 kD BCR-ABL protein b3a2 (p210b3a2) were previously shown to bind to several HLA class I and II alleles. We have found that b3a2 peptide-specific CD4-positive T-helper cells were able to recognize p210b3a2-positive chronic myelogenous leukemia (CML) blasts in a DR4 restricted manner. Until now, there were no reports of b2a2 breakpoint-specific human T-cell responses. Here we show that repetitive stimulation of T lymphocytes with a 17mer peptide covering the fusion region in p210b2a2 also leads to specific T-cell responses. CD4 and CD4/CD8 double-positive clones obtained from a b2a2 peptide-specific cell line were cytotoxic and proliferative in an HLA-DR2a (DRB5*0101) restricted fashion. Autologous Epstein-Barr virus (EBV) transformed cells, expressing BCR-ABL(b2a2) on transfection, and allogeneic HLA-DR matched p210b2a2-positive cells from CML patients were, however, not lysed. BCR-ABL peptide-specific T-cell clones did respond to autologous EBV cells transfected with invariant chain (li) cDNA in which the HLA class II-associated invariant chain peptide (CLIP) was replaced by a BCR-ABL b2a2 fusion oligonucleotide sequence, illustrating the potential of these T cells to recognize an endogenous BCR-ABL(b2a2) ligand.

[1]  J. Melo,et al.  p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. , 1996, Blood.

[2]  O. Rötzschke,et al.  Origin, structure and motifs of naturally processed MHC class II ligands. , 1994, Current opinion in immunology.

[3]  C. Verfaillie,et al.  Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. , 1992, Blood.

[4]  J. Melo,et al.  The ABL-BCR Fusion Gene Is Expressed in Chronic Myeloid Leukemia , 1993 .

[5]  P. Marrack,et al.  Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. , 1998, Immunity.

[6]  J. Drijfhout,et al.  Clip binds to HLA class II using methionine-based, allele-dependent motifs as well as allele-independent supermotifs. , 1995, Molecular immunology.

[7]  G. Tricot,et al.  Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. , 1993, Blood.

[8]  D. Accapezzato,et al.  Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes , 1996 .

[9]  G. Fields,et al.  Solid Phase Peptide Synthesis Utilizing 9-Fluorenylmethoxycarbonylamino Acids , 1990 .

[10]  J. Wang.  Negative regulation of c-abl tyrosine kinase by its variable N-terminal amino acids. , 1988, Oncogene research.

[11]  J. Sidney,et al.  Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. , 1995, Blood.

[12]  P. J. van den Elsen,et al.  Differential usage of T cell receptor V gene segments in CD4+ and CD8+ subsets of T lymphocytes in monozygotic twins. , 1993, Journal of immunology.

[13]  Kees Stam,et al.  Structural organization of the bcr gene and its role in the Ph′ translocation , 1985, Nature.

[14]  A. Bernheim,et al.  Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. , 1998, Blood.

[15]  G. Morgan,et al.  Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. , 1991, Blood.

[16]  Y. Nishimura,et al.  CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. , 1998, Blood.

[17]  J. Bodmer,et al.  Microcytotoxicity assay using mouse L cells transfected with human MHC class II genes. A method and its application. , 1990, Tissue antigens.

[18]  Rekha Khanna,et al.  Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1. , 1996, Virology.

[19]  J. Melo,et al.  The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. , 1998, Blood.

[20]  B. Malissen,et al.  Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. , 2008, Tissue antigens.

[21]  H. Kantarjian,et al.  Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. , 1989, Blood.

[22]  G. Pawelec,et al.  Extrathymic T cell differentiation in vitro from human CD34+ stem cells , 1998, Journal of leukocyte biology.

[23]  R. Germain,et al.  Unexpectedly complex regulation of CD4/CD8 coreceptor expression supports a revised model for CD4+CD8+ thymocyte differentiation. , 1996, Immunity.

[24]  C Oseroff,et al.  HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. , 1994, Journal of immunology.

[25]  R. Houghten,et al.  Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. , 1998, Journal of immunology.

[26]  F. Lemonnier,et al.  Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. , 1998, The Journal of clinical investigation.

[27]  N. Heisterkamp,et al.  The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript , 1986, Molecular and cellular biology.

[28]  J. Strominger,et al.  Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. , 1987, The Journal of biological chemistry.

[29]  R. Offringa,et al.  Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Bruce A. Roe,et al.  Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene , 1986, Cell.

[31]  W. Jy.  Negative regulation of c-abl tyrosine kinase by its variable N-terminal amino acids. , 1988 .

[32]  H. Saito,et al.  Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients. , 1993, Blood.

[33]  W. Chen.  T cell immunity to the joining region of p210^ protein. , 1992 .

[34]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[35]  C. Janeway,et al.  The specificity and orientation of a TCR to its peptide-MHC class II ligands. , 1996, Immunity.

[36]  J. Trowsdale,et al.  Analysis of HLA-DR glycoproteins by DNA-mediated gene transfer. Definition of DR2 beta gene products and antigen presentation to T cell clones from leprosy patients , 1988, The Journal of experimental medicine.

[37]  Wei Chen,et al.  T-cell immunity to the joining region of p210BCR-ABL protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Melo,et al.  The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. , 1996, Blood.

[39]  K. Papadopoulos,et al.  Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. , 1997, Blood.

[40]  G. Martinelli,et al.  Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. , 1996, Blood.

[41]  G. Chelvanayagam,et al.  Peptide mimics of a tumor antigen induce functional cytotoxic T cells , 1998, Nature Biotechnology.

[42]  G. Huez,et al.  Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. , 1995, Blood.

[43]  C. Melief,et al.  Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. , 1996, Blood.

[44]  C. Melief,et al.  Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. , 1995, Leukemia.

[45]  T. Ottenhoff,et al.  Specific killing of cytotoxic T cells and antigen-presenting cells by CD4+ cytotoxic T cell clones. A novel potentially immunoregulatory T-T cell interaction in man , 1990, The Journal of experimental medicine.

[46]  K. Tadokoro,et al.  Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. , 1998, Blood.

[47]  G. Fields,et al.  Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. , 2009, International journal of peptide and protein research.

[48]  J. McKenzie,et al.  HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. , 1997, Blood.

[49]  A. Sette,et al.  Specific human cellular immunity to bcr-abl oncogene-derived peptides. , 1996, Blood.

[50]  Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. , 1992 .

[51]  G. Pawelec,et al.  BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. , 1996, Blood.